Skip to main content
Bioceltix S.A. logo

Bioceltix S.A. — Investor Relations & Filings

Ticker · BCX ISIN · PLBCLTX00019 LEI · 259400QZD5JYK8SLZU51 WAR Manufacturing
Open in API
Filings indexed 270 across all filing types
Latest filing 2022-09-28 Interim / Quarterly Rep…
Country PL Poland
Listing WAR BCX

About Bioceltix S.A.

https://bioceltix.com/en/

Bioceltix S.A. is a biopharmaceutical company that develops stem cell-based medicinal products for veterinary use. The company focuses on creating therapies that utilize Mesenchymal Stem Cells (MSCs) as the active pharmaceutical ingredient. Its product pipeline is aimed at treating immunological and inflammatory conditions in companion animals, including dogs, cats, and horses. A key area of development includes treatments for conditions such as atopic dermatitis in dogs and degenerative joint disease.

Recent filings

Filing Released Lang Actions
Sprawozdanie Zarządu z działalności jako część załączonego Raportu za I półrocze 2022 r.
Interim / Quarterly Report Classification · 100% confidence The document is titled 'RAPORT PÓŁROCZNY' (Semi-annual Report) for Bioceltix S.A. for the first half of 2022. It contains comprehensive financial statements, management discussion, and operational updates for the specified period. It is not an announcement of a report, but the report itself, containing substantive financial data and analysis, fitting the definition of an Interim/Quarterly Report. H1 2022
2022-09-28 Polish
Oświadczenie Zarządu jako część załączonego Raportu za I półrocze 2022 r.
Interim / Quarterly Report Classification · 100% confidence The document is titled 'RAPORT PÓŁROCZNY' (Semi-annual Report) for Bioceltix S.A. for the first half of 2022. It contains comprehensive financial statements, management discussion, and operational updates for the specified period. It is not an announcement of a report, but the report itself, containing substantive financial data and analysis, fitting the definition of an Interim/Quarterly Report. H1 2022
2022-09-28 Polish
Raport firmy audytorskiej z przeglądu półrocznego skróconego sprawozdania finansowego za okres 01.01.2022-30.06.2022 Bioceltix S.A.
Audit Report / Information Classification · 99% confidence The document is explicitly titled "Raport niezależnego biegłego rewidenta z przeglądu półrocznego skróconego sprawozdania finansowego" (Report of the independent auditor on the review of the condensed half-year financial statements). It details the review procedures performed on the financial statements for the period ending June 30, 2022, and concludes with a formal finding based on that review. This directly matches the definition of an Audit Report / Information (AR), which covers standalone audit reports and results of internal/regulatory stress tests, distinguishing it from a full Annual Report (10-K) or a simple Earnings Release (ER). The content is the audit opinion itself, not an announcement of the report (RPA). H1 2022
2022-09-28 Polish
Warunkowa rejestracja akcji serii I w Krajowym Depozycie Papierów Wartościowych S.A. - Content (PL)
Share Issue/Capital Change Classification · 98% confidence The document is a formal announcement from the Management Board of Bioceltix S.A. regarding the registration of 140,536 new Series I shares by the National Securities Depository in Warsaw (KDPW). The text explicitly mentions the issuance of new shares ('emisji nowych akcji zwykłych na okaziciela serii I') and the process for admitting these shares to trading on a regulated market. This directly relates to changes in the company's capital structure and share issuance. Therefore, the most appropriate classification is 'Share Issue/Capital Change' (SHA). The document is short and appears to be the primary announcement, not just a notice about another report.
2022-09-22 Polish
Terminy publikacji raportów okresowych w 2022 roku - Content (PL)
Report Publication Announcement Classification · 98% confidence The document text, written in Polish, explicitly states the dates ('terminy') for the publication of periodic reports ('raportów okresowych') by the Issuer ('Emitent') for the year 2022, specifically mentioning the half-year report and the Q3 report. It also mentions that the Q2 report will not be published. This content is an announcement about the schedule of future financial report releases, not the reports themselves. This aligns perfectly with the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports.
2022-09-08 Polish
Dopuszczenie i wprowadzenie akcji Spółki serii A-G do obrotu na rynku regulowanym - Content (PL)
Share Issue/Capital Change Classification · 99% confidence The document is a formal announcement from the Management Board of Bioceltix S.A. regarding the admission and introduction of a specific number of company shares (series A-G) to trading on the regulated market of the Warsaw Stock Exchange (GPW), effective September 5, 2022. It also mentions the exclusion of these shares from the NewConnect system. Crucially, it references the prospectus approved by the Polish Financial Supervision Authority (KNF) as the legally binding document for this admission. This action—the admission of shares to a regulated market following a prospectus approval—is a significant capital market event related to the structure and trading of the company's stock. While it involves capital structure changes, the core event described is the formal listing/admission process on the main market, which is a type of financing/capital activity. Given the options, 'Capital/Financing Update' (CAP) is the most appropriate fit as it covers fundraising and capital structure changes related to listing. It is not a general regulatory filing (RNS) because it describes a specific, defined corporate action (listing admission). It is too detailed to be a simple 'Share Issue/Capital Change' (SHA) which usually covers splits or new issues outside of a formal listing process, although there is overlap. CAP is chosen because the context is the transition to the main regulated market, often following a capital event like a prospectus issuance.
2022-08-30 Polish

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.